Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) ...
Voyager Provides Update on SOD1 ALS Gene Therapy Program
Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...
Goldman Sachs cuts Silence Therapeutics stock rating to Sell
Goldman Sachs initiated coverage on Silence Therapeutics (NASDAQ:SLN), currently trading at $4.92 with a market cap of $232.3 million, with a Sell rating and a price target of $6.00. According to ...
News Medical5h
Adrenomedullin hormone as key driver of insulin resistance in obesity-linked type 2 diabetes
Researchers investigate the underlying mechanisms of endothelial insulin resistance involved in obesity-associated diabetes.
Goldman starts Silence Therapeutics at Sell on ‘undifferentiated’ data
Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA ...